Incyte Genomics Inc
Symbol: INCY (NASDAQ)
85.73
▼ (-0.60%) -0.520
Company Description:
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Key Stats
- Today's Open: $86.743
- Today's High: $86.743
- Today's Low: $85.73
- Today's Volume: 0
- Yesterday Close: $86.25
- Yesterday High: $86.9399
- Yesterday Low: $84.54
- Yesterday Volume: 1.91M
- Last Min Volume: 0
- Last Min High: $86.743
- Last Min Low: $85.73
- Last Min VWAP: $0
Company Profile
- Name: Incyte Genomics Inc
- Website: https://www.incyte.com
- Listed Date: 1993-11-03
- Location: WILMINGTON, DE
- Market Status: Active
- CIK Number: 0000879169
- SIC Code: 8731
- SIC description: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
- Market Cap: $16.84B
- Round Lot: 100
- Outstanding Shares: 195.28M
- Asset Type: CS
RECENT FILINGS FOR INCY
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-04 | 4 | View |
| 2025-09-02 | 144 | View |
| 2025-08-27 | 4 | View |
| 2025-08-27 | 3 | View |
| 2025-08-19 | 4 | View |
| 2025-08-15 | 144 | View |
| 2025-08-13 | 144 | View |
| 2025-08-12 | 144 | View |
| 2025-08-07 | 8-K | View |
| 2025-08-06 | 4 | View |
| 2025-08-05 | 3 | View |
| 2025-08-04 | 144 | View |
| 2025-07-29 | 10-Q | View |
| 2025-07-29 | 8-K | View |
| 2025-07-23 | 4 | View |
| 2025-07-21 | 144 | View |
| 2025-07-17 | 4 | View |
| 2025-07-17 | 4 | View |
| 2025-07-17 | 4 | View |
| 2025-07-17 | 4 | View |
Latest News on INCY